Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.
已完结
10
由 Aixuexi 发布于 2026/6/3 17:07:14
DOI:10.1016/S0140-6736(26)00968-2
作者：Anwen Xiong,?Wenxiu Yao,?Wei Zheng,?Yan Yu,?Peng Chen,?Hua Zhong,?Junyou Ge,?Hui Wang,?Bolin Chen,?Haiyong Wang,?Yun Fan,?Yunpeng Yang,?Xingxiang Pu,?Xia Song,?Qiming Wang,?Xiaobo Du,?Zhangzhou Huang,
文献类型：期刊论文
补充材料：只需要正文
作者：Anwen Xiong,?Wenxiu Yao,?Wei Zheng,?Yan Yu,?Peng Chen,?Hua Zhong,?Junyou Ge,?Hui Wang,?Bolin Chen,?Haiyong Wang,?Yun Fan,?Yunpeng Yang,?Xingxiang Pu,?Xia Song,?Qiming Wang,?Xiaobo Du,?Zhangzhou Huang,
文献类型：期刊论文
补充材料：只需要正文
Elsevier
其它数据库
京公网安备 11010802042870号
